Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

被引：0
|
作者：
Peng Yuan
Jianzhong Shentu
Jianming Xu
Wendy Burke
Kate Hsu
Maria Learoyd
Min Zhu
Binghe Xu
机构：
[1] Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC),National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] The First Affiliated Hospital of Zhejiang University,Research Center for Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease
[3] Academy of Military Medical Sciences,Affiliated Hospital Cancer Center, The 307th Hospital of Chinese People’s Liberation Army
[4] Covance Clinical Research Unit,undefined
[5] AstraZeneca,undefined
[6] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Chinese patients; Olaparib; Paclitaxel; PARP inhibitor; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：963 / 974
页数：11
相关论文
共 50 条
  • [1] Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
    Yuan, Peng
    Shentu, Jianzhong
    Xu, Jianming
    Burke, Wendy
    Hsu, Kate
    Learoyd, Maria
    Zhu, Min
    Xu, Binghe
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 963 - 974
  • [2] Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    E Dean
    M R Middleton
    T Pwint
    H Swaisland
    J Carmichael
    P Goodege-Kunwar
    M Ranson
    British Journal of Cancer, 2012, 106 : 468 - 474
  • [3] Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    Dean, E.
    Middleton, M. R.
    Pwint, T.
    Swaisland, H.
    Carmichael, J.
    Goodege-Kunwar, P.
    Ranson, M.
    BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 468 - 474
  • [4] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    G Del Conte
    C Sessa
    R von Moos
    L Viganò
    T Digena
    A Locatelli
    E Gallerani
    A Fasolo
    A Tessari
    R Cathomas
    L Gianni
    British Journal of Cancer, 2014, 111 : 651 - 659
  • [5] Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    Del Conte, G.
    Sessa, C.
    von Moos, R.
    Vigano, L.
    Digena, T.
    Locatelli, A.
    Gallerani, E.
    Fasolo, A.
    Tessari, A.
    Cathomas, R.
    Gianni, L.
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 651 - 659
  • [6] Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
    van der Noll, Ruud
    Ang, Joo Ern
    Jager, Agnes
    Marchetti, Serena
    Mergui-Roelvink, Marja
    De Bono, Johann Sebastian
    Lolkema, Martijn
    Brunetto, Andre
    Arkenau, Hendrik-Tobias
    De Jonge, Maja J.
    van der Biessen, Diane
    Tchakov, Ilian
    Bowen, Karin
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
    Christian Rolfo
    Judith de Vos-Geelen
    Nicolas Isambert
    L. Rhoda Molife
    Jan H. M. Schellens
    Jacques De Grève
    Luc Dirix
    Peter Grundtvig-Sørensen
    Guy Jerusalem
    Karin Leunen
    Morten Mau-Sørensen
    Ruth Plummer
    Maria Learoyd
    Wendy Bannister
    Anitra Fielding
    Alain Ravaud
    Clinical Pharmacokinetics, 2019, 58 : 1165 - 1174
  • [8] Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment
    Rolfo, Christian
    de Vos-Geelen, Judith
    Isambert, Nicolas
    Molife, L. Rhoda
    Schellens, Jan H. M.
    De Greve, Jacques
    Dirix, Luc
    Grundtvig-Sorensen, Peter
    Jerusalem, Guy
    Leunen, Karin
    Mau-Sorensen, Morten
    Plummer, Ruth
    Learoyd, Maria
    Bannister, Wendy
    Fielding, Anitra
    Ravaud, Alain
    CLINICAL PHARMACOKINETICS, 2019, 58 (09) : 1165 - 1174
  • [9] A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
    Lassen, U.
    Molife, L. R.
    Sorensen, M.
    Engelholm, S-A
    Vidal, L.
    Sinha, R.
    Penson, R. T.
    Buhl-Jensen, P.
    Crowley, E.
    Tjornelund, J.
    Knoblauch, P.
    de Bono, J. S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (01) : 12 - 17
  • [10] A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
    U Lassen
    L R Molife
    M Sorensen
    S-A Engelholm
    L Vidal
    R Sinha
    R T Penson
    P Buhl-Jensen
    E Crowley
    J Tjornelund
    P Knoblauch
    J S de Bono
    British Journal of Cancer, 2010, 103 : 12 - 17
12345